Rad-X Transcends Virtual Barrier; Researched into Real Drug that ALSO CURES CANCER - Polidicks

It's amazing what you find when searching Wikipedia: [quote=BBC News] A drug which may protect the body against damage from radiation has been developed by US scientists. It is hoped it could make radiotherapy safer for people with cancer and could also be used in the event of a "dirty bomb" or nuclear disaster. Known as CBLB502, and so far tested in animals, it switches on a biological mechanism that helps healthy cells survive blasts of radiation. The findings published in Science are set to be tested in clinical trials. Radiation kills cells by causing damage which encourages cell suicide, or apoptosis. But healthy cells may be killed alongside tumour cells in the process which is why radiologists need to target the tumour as specifically as possible. If the protective properties seen in this laboratory study can be reproduced in people with cancer, this could be an important step towards reducing side effects for people having radiotherapy Dr Joanna Owens, Cancer Research UK Researchers developed the drug after looking at how some resistant cancer cells are able to withstand radiotherapy. It works by inhibiting the protein that initiates the cell suicide programme. Studies in animals suggest CBLB502 protects healthy cells in the bone marrow and digestive tract against radiation but does not seem to protect tumour cells which remain vulnerable to treatment. Mice and monkeys injected with the drug between 45 minutes and 24 hours before being subjected to normally lethal radiation were more likely to survive or live longer than untreated animals, the researchers found. Side-effects One risk of preventing cell death is that defective cells may be allowed to survive which could then turn cancerous. However, the researchers found no sign of this happening in the laboratory tests on mice. Also, there were no apparent side effects. Protecting healthy cells against the effects of radiation may allow cancer patients to receive higher doses of radiotherapy, or longer courses of treatment. The drug may also be useful in protecting against fall out from a nuclear disaster, such as Chernobyl, or the effects of a terrorist "dirty bomb". Dr Andrei Gudkov from the Lerner Research Institute in Cleveland, Ohio, said they had set out to enable healthy cells to imitate the ability of tumour cells to avoid cell death. But they had to develop a way of making this effect temporary and reversible. "We demonstrated the drug is efficacious when injected before radiation and after radiation. "In summary, CBLB502 reduces radiation toxicity without diminishing the therapeutic anti-tumour effect of radiation and without promoting radiation-induced carcinogenicity." Dr Joanna Owens, science information officer at Cancer Research UK, said: "These are interesting results and we look forward to following the progress of CBLB502 through planned clinical trials. "If the protective properties seen in this laboratory study can be reproduced in people with cancer, this could be an important step towards reducing side effects for people having radiotherapy." [/quote] [url]http://news.bbc.co.uk/2/hi/health/7341336.stm[/url] [IMG]http://i155.photobucket.com/albums/s297/Chris122990/2091_CBO_RadX.jpg[/IMG] [quote=Cleveland Biolabs Press Release] BUFFALO, NY -- (MARKET WIRE) -- 01/20/11 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has accumulated preclinical data demonstrating that CBLB502, a drug under development to treat exposure to radiation, has direct anticancer effect in several transplanted cancer models grown in mice and rats including colon and lung cancer, lymphoma and melanoma. In one of the animal models of transplanted colon cancer, CBLB502 treatment resulted in complete tumor regression with no recurrence of the disease in a large percentage of animals. Experimental results suggest that CBLB502's anticancer effect stems from the same mechanism which underlies its ability to treat radiation exposure and which involves tissue-specific activation of innate immune response mediated by CBLB502's interaction with its receptor, TLR5. Antitumor effects largely depend on the expression of TLR5 by the tumor. However, in the case of tumors residing in the liver, the organ which has been identified as the natural primary target site for CBLB502 activity, tumors become effectively suppressed as a result of host immune system attack regardless of their TLR5 status. This characteristic makes liver metastasis a favorable target for potential anticancer applications of CBLB502. Andrei Gudkov, Ph.D., D. Sc., Chief Scientific Officer of Cleveland BioLabs and Senior Vice President of Basic Science at Roswell Park Cancer Institute, commented, "We are very excited by these initial results, which extend CBLB502's potential medical applications in cancer treatment from use as a supportive care agent to reduce toxicities of radio and chemotherapy to use as a direct anticancer agent. We believe that clinical development of CBLB502's potential immunotherapy effects may be pursued in parallel to or in some cases as part of, our prior plan for supportive care applications, and we are currently modifying our development plan to integrate this important new opportunity. We expect to complete these adjustments shortly and move forward into the clinic." William Cance, M.D., Surgeon-in-Chief and Chair of the Department of Surgical Oncology at Roswell Park Cancer Institute, stated, "I have always thought that CBLB502 had the potential to revolutionize several areas of clinical cancer treatment through its ability to protect normal tissues. With this recent demonstration of direct anticancer activity, I believe the potential for CBLB502 to achieve broad clinical application becomes even more likely. I am especially excited about the observations regarding CBLB502's effect on tumors in the liver, as this property could make a significant difference in a currently hopeless category of patients with advanced liver metastasis." These findings were the result of research into the tissue specific activity of CBLB502, which was funded by a Grand Opportunities (GO) grant under the American Recovery and Reinvestment Act of 2009 from the Office of the Director and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). This direction of research follows previous preclinical demonstrations of CBLB502's specific protection of normal tissues versus tumors, and its ability to protect such tissues in animal models of fractioned, localized radiation mimicking clinical regimens. About Cleveland BioLabs, Inc. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at [url]http://www.cbiolabs.com[/url]. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. These factors include, among others, the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company's R&D grants and contracts; the Company's failure to successfully and timely develop new products; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; the potential for significant product liability claims; and the Company's ability to comply with various safety, environmental and other governmental regulations. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission. [/quote] [url]http://www.streetinsider.com/Press+Releases/Cleveland+BioLabs+Announces+Potential+Direct+Anticancer+Effect+of+CBLB502/6225932.html[/url]

Somebody got the swift learner perk

Bravo.

It doesn't cure cancer.

[QUOTE=Jookia;27866254]It doesn't cure cancer.[/QUOTE] [quote]In one of the animal models of transplanted colon cancer, CBLB502 treatment resulted in complete tumor regression with no recurrence of the disease in a large percentage of animals.[/quote] Because that totally doesn't mean it cured the cancer.

[QUOTE]Protecting healthy cells against the effects of radiation may allow cancer patients to receive higher doses of radiotherapy, or longer courses of treatment.[/QUOTE] It seems like it just helps cancer patients more but doesn't completely cure cancer. Everyone knows that Rad-X only provides resistance. RadAway will cure cancer, etc.

[QUOTE=orgornot;27866298]It seems like it just helps cancer patients more but doesn't completely cure cancer. Everyone knows that Rad-X only provides resistance. RadAway will cure cancer, etc.[/QUOTE] The article said that it [B]protects[/B] against radiation, if you bothered to read it. Seriously, it was the first sentence edit: maybe it's a mix between the two?

[QUOTE=Kiwi Bird;27866682]The article said that it [B]protects[/B] against radiation, if you bothered to read it. Seriously, it was the first sentence edit: maybe it's a mix between the two?[/QUOTE] doesnt see the obvious joke...

I'd be more trusting if they could explain how it doesn't increase the incidence of cancer. Still, instead rad-death or cancer in a while, I know which one I'd take.

k lets nuke the motherfuckers now guys

I'm 100% sure we'll never hear of this again.

From the description, it seems to activate additional cellular and genetic repair enzymes that repair any damage made by radiation, with a side effect of reversing cancer.

And just like many cures before it, it'll get lost in bureaucracy and will never be heard of again because the pharmaceutical companies pump too much money into election campaigns.

[QUOTE=Canuhearme?;27867180]I'm 100% sure we'll never hear of this again.[/QUOTE] Yeah, these seemingly miraculous discoveries always seem to drop off the face of the earth.

Go America!

[QUOTE=Canuhearme?;27867180]I'm 100% sure we'll never hear of this again.[/QUOTE] If we would add all these drugs that cure cancer and merge it into one, we'd get the real cure. Seeing as there must be like 1000 of them by now.

[QUOTE=hypno-toad;27868719]Yeah, these seemingly miraculous discoveries always seem to drop off the face of the earth.[/QUOTE] Sadly yeah...

Nice, now its ok to use nuclear weapons

I Am Legend anyone..?

[QUOTE=hypno-toad;27868719]Yeah, these seemingly miraculous discoveries always seem to drop off the face of the earth.[/QUOTE] That's because they have to go through extensive testing and trials. Hell, this is still animal testing. They have probably ten years before they can even think of a public release.

Oh America, what else do you have up your sleeve?

I hope they make the brand name Rad-X, that'd be awesome.

Useful.

I was sad when I realized the articles didn't mention the video-game item. :frown:

Remember to put on your old surgeon's uniform before doing anything, it'll automatically increase resistance. :science:

[QUOTE=Canuhearme?;27867180]I'm 100% sure we'll never hear of this again.[/QUOTE] Like the synthetic oil made by bacteria? Like the succesfull treatment of cancer using nanotechnology? It's too true, I wonder why these things are just dismissed and forgotten.

[QUOTE=Mr. N;27883511]Like the synthetic oil made by bacteria? Like the succesfull treatment of cancer using nanotechnology? It's too true, I wonder why these things are just dismissed and forgotten.[/QUOTE] Typically the "discovery" is exaggerated. The research an article talks about might discuss how the manipulation of a protein may halt the growth of cancer...and of course the media labels it as "CURE FOR CANCER FOUND".

Except in this case it shrinks the tumor into nothing and prevents it from reforming. I believe that's the very definition of curing something.

Scientific breakthroughs are what give me a renewed hope for humanity.

All those points I put into medicine are paying off.